MedPath

ROSWELL PARK CANCER INSTITUTE

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

An Alternative Dosing Schedule of Varenicline for Smoking Cessation

Phase 2
Completed
Conditions
Smoking Cessation
Interventions
Drug: placebo
First Posted Date
2009-02-04
Last Posted Date
2017-05-30
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
60
Registration Number
NCT00835900
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2
Terminated
Conditions
Leukemia
Interventions
Genetic: cytogenetic analysis
Genetic: protein expression analysis
Other: immunologic technique
Other: pharmacological study
First Posted Date
2008-12-24
Last Posted Date
2016-08-17
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
21
Registration Number
NCT00814164
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance

Not Applicable
Withdrawn
Conditions
Prostate Cancer
First Posted Date
2008-11-24
Last Posted Date
2013-07-25
Lead Sponsor
Roswell Park Cancer Institute
Registration Number
NCT00796874

Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer

Not Applicable
Terminated
Conditions
Breast Cancer
Precancerous Condition
Interventions
Other: No Intervention
Dietary Supplement: Ground Flaxseed
First Posted Date
2008-11-21
Last Posted Date
2016-06-03
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
20
Registration Number
NCT00794989
Locations
🇺🇸

University of Chicago Medicine, Chicago, Illinois, United States

🇺🇸

Roswell Cancer Park Institute, Buffalo, New York, United States

Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Dietary Supplement: selenomethionine
Other: placebo
First Posted Date
2008-08-18
Last Posted Date
2023-10-02
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
55
Registration Number
NCT00736645
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer

Phase 2
Withdrawn
Conditions
Prostate Cancer
Interventions
Dietary Supplement: selenomethionine
Other: placebo
First Posted Date
2008-08-15
Last Posted Date
2012-02-06
Lead Sponsor
Roswell Park Cancer Institute
Registration Number
NCT00736164

Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery

Not Applicable
Completed
Conditions
Lung Cancer
First Posted Date
2008-08-12
Last Posted Date
2017-10-18
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
100
Registration Number
NCT00732563
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer

Not Applicable
Completed
Conditions
Lung Cancer
Precancerous Condition
Tobacco Use Disorder
Interventions
Other: laboratory biomarker analysis
Other: pharmacological study
First Posted Date
2008-06-05
Last Posted Date
2018-06-04
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
16
Registration Number
NCT00690924
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Phase 2
Terminated
Conditions
Gastric Cancer
Interventions
First Posted Date
2008-05-23
Last Posted Date
2015-01-08
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
8
Registration Number
NCT00683787
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx

Phase 1
Completed
Conditions
Head and Neck Cancer
Interventions
Procedure: laser therapy
First Posted Date
2008-05-09
Last Posted Date
2018-10-17
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
29
Registration Number
NCT00675233
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2025. All Rights Reserved by MedPath